Centre Number
Candidate Number
*P69506A0128*
Turn over    
Total Marks
Candidate surname
Other names
Please check the examination details below before entering your candidate information
Paper
reference


Instructions
•	Use black ink or ball‑point pen.
•	Fill in the boxes at the top of this page with your name,  
centre number and candidate number.
•	Answer all questions.
•	Answer the questions in the spaces provided  
– there may be more space than you need.
•	Show all your working out in calculations and include units where appropriate.
Information
•	The total mark for this paper is 90.
•	The marks for each question are shown in brackets 
– use this as a guide as to how much time to spend on each question.
•	In questions marked with an asterisk (*), marks will be awarded for your ability 
to structure your answer logically, showing how the points that you make are 
related or follow on from each other where appropriate.
Advice
•	Read each question carefully before you start to answer it.
•	Try to answer every question.
•	Check your answers if you have time at the end.
You must have:
Scientific article (enclosed), scientific calculator, ruler, HB pencil
Biology
International Advanced Level
UNIT 5: Respiration, Internal Environment, 
Coordination and Gene Technology
WBI15/01
Time 1 hour 45 minutes
Pearson Edexcel International Advanced Level
P69506A
©2022 Pearson Education Ltd.
L:1/1/1/1/1/
PMT


--- Page Break ---

*P69506A0228*
2
	
 
 
Answer ALL questions. Write your answers in the spaces provided.
Some questions must be answered with a cross in a box . If you change your mind about an 
answer, put a line through the box 
 and then mark your new answer with a cross .
1	 The photograph shows a transmission electron micrograph of a mitochondrion and 
surrounding cytoplasm.
X
Y
(Source: © CNRI / SCIENCE PHOTO LIBRARY)
	
(a)	 The mitochondrion shown in the diagram is 2000 nm in length.
	
	
Calculate the width of this mitochondrion between X and Y.
(2)
Answer .............................................................. nm
PMT


--- Page Break ---

*P69506A0328*
Turn over     
3
	
 
 
	
(b)	 Describe how ATP is synthesised by oxidative phosphorylation in 
the mitochondrion.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
	
(c)	 Describe how ATP is used to supply energy for biological processes.
(2)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 1 = 7 marks)
PMT


--- Page Break ---

*P69506A0428*
4
	
 
 
2	 Muscles, bones and joints enable movement of the skeleton.
	
(a)	 (i)	 Which structure attaches one bone to another bone at a flexible joint?
(1)
	
A	 actin
	
B	 ligament
	
C	 synapse
	
D	 tendon
	
	
(ii)	 How many of the statements about joints are correct?
(1)
•	
antagonistic pairs of muscles move the bones at a joint
•	
muscles acting on a joint are myogenic
•	
tendons are more elastic than ligaments
	
A	 0
	
B	 1
	
C	 2
	
D	 3
PMT


--- Page Break ---

*P69506A0528*
Turn over     
5
	
 
 
	
(b)	 Usain Bolt’s world record of 9.58 seconds for the 100 m men’s sprint is unbeaten.
(Source: © Ian MacNicol / Getty Images)
	
	
(i)	 What is the role of myoglobin in muscle fibres?
(1)
	
A	 it is an enzyme that reacts with myosin
	
B	 it is part of the sarcolemma involved in the release of calcium ions
	
C	 to act as an immediate source of energy
	
D	 to provide oxygen for muscles
	
	
(ii)	 Explain why the muscles of a sprinter have a high percentage of 
fast twitch fibres.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P69506A0628*
6
	
 
 
	
(c)	 In an investigation, an athlete ran for 10 minutes on a running machine moving at 
constant speed.
	
	
The investigation was repeated at seven running speeds.
	
	
At each speed, the heart rate and lactate concentration in the blood of the athlete 
were measured.
	
	
The results are shown in the graph.
running machine speed / km h–1
heart 
rate 
/ bpm
0
8
10
12
14
16
18
20
200
180
160
140
120
100
80
60
40
20
0
40
36
32
28
24
20
16
12
8
4
0
lactate 
concentration 
/ mmol dm–3
heart rate
lactate concentration
	
	
Comment on the results of this investigation.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 2 = 9 marks)
PMT


--- Page Break ---

*P69506A0728*
Turn over     
7
	
 
 
3	 Whales are large mammals. 
	
The photograph shows a beluga whale and a human diver.
(Source: © Andrey Nekrasov/Alamy Stock Photo)
	
(a)	 (i)	 A beluga whale can become habituated to human divers.
	
	
	
How many of the following statements about habituation are correct?
(1)
•	
habituation is an example of anatomical adaptation
•	
habituation is only observed in mammals
•	
habituation only occurs after repeated exposure to the same stimulus
	
A	 0
	
B	 1
	
C	 2
	
D	 3
PMT


--- Page Break ---

*P69506A0828*
8
	
 
 
	
	
(ii)	 A beluga whale can respond to a stimulus using a spinal reflex arc.
	
	
	
Which row is correct?
(1)
	
A	
	
B	
	
C	
	
D	  
Location of relay neurone
Location of cell body on 
the sensory neurone
grey matter of spinal cord
at the end of the axon
grey matter of spinal cord
in the middle of the axon
white matter of spinal cord
at the end of the axon
white matter of spinal cord
in the middle of the axon
PMT


--- Page Break ---

*P69506A0928*
Turn over     
9
	
 
 
	
(b)	 The heart rate of a whale changes when it is diving.
	
	
The graph shows the changes in heart rate that occur during dives of 
different durations.
	
	
The maximum heart rate at the surface is when the whale returns to the surface 
after a dive.
maximum heart rate at 
the surface after a dive
maximum heart rate 
during a dive
minimum heart rate 
during a dive
dive duration / min
heart rate 
/ bpm
0
2
4
6
8
10
12
14
16
18
40
35
30
25
20
15
10
5
0
	
	
(i)	 Comment on the changes in heart rate of the whale when diving.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P69506A01028*
10
	
 
 
	
	
(ii)	 Explain how the changes in heart rate are controlled when the whale returns 
to the surface immediately after the dive.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 3 = 8 marks)
PMT


--- Page Break ---

*P69506A01128*
Turn over     
11
	
 
 
4	 The kidneys perform important roles in filtering the blood and maintaining fluid 
levels in the body.
	
Each kidney contains up to a million functioning units called nephrons.
	
Each nephron consists of a filtering unit of tiny blood vessels called a glomerulus that 
is attached to a tubule.
	
(a)	 The diagram shows part of a human kidney.
	
	
(i)	 Draw an arrow on the diagram to show the location of a single Bowman’s 
capsule (renal capsule).
medulla
pelvis
cortex
(1)
PMT


--- Page Break ---

*P69506A01228*
12
	
 
 
	
	
(ii)	 Where in the kidney are most amino acids reabsorbed from the nephron?
(1)
	
A	 collecting duct
	
B	 distal tubule
	
C	 loop of Henle
	
D	 proximal tubule
	
	
(iii)	Which row shows the correct pathway taken by a water molecule through the 
kidney nephron?
(1)
	
A	
	
B	
	
C	
	
D	  
	
(b)	 Explain how the loop of Henle acts as a countercurrent multiplier to produce 
concentrated urine.
(4)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
Route through nephron  
collecting duct
proximal tubule
distal tubule
glomerulus
glomerulus
proximal tubule
distal tubule
collecting duct
glomerulus
distal tubule
collecting duct
proximal tubule
proximal tubule
glomerulus
distal tubule
collecting duct
PMT


--- Page Break ---

*P69506A01328*
Turn over     
13
	
 
 
	
(c)	 Describe how ADH is involved in the control of the water potential of the blood.
(4)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 4 = 11 marks)
PMT


--- Page Break ---

*P69506A01428*
14
	
 
 
5	 Animals and plants can detect and respond to light.
	
(a)	 Rod cells respond to light by producing action potentials in the optic nerve.
	
	
(i)	 In which structure are rod cells located?
(1)
	
A	 iris
	
B	 pupil
	
C	 retina
	
D	 spinal cord
	
	
(ii)	 Describe the role of rhodopsin in rod cells.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P69506A01528*
Turn over     
15
	
 
 
	
*(b)	 The drawing shows the results of some experiments investigating phototropisms.
	
	
The diagram shows a coleoptile of a seedling.
coleoptile
roots
Experiment 1:
light
light
light
intact coleoptile illuminated 
from one side
tip of coleoptile removed 
and remaining coleoptile 
illuminated from one side
black cap placed on tip of 
coleoptile and coleoptile 
illuminated from one side
	
Experiment 2a: 	
Experiment 2b:
plastic sheet inserted below the tip 
of the coleoptile and the coleoptile  
illuminated from one side
gel layer placed below the tip of 
the coleoptile and the coleoptile 
illuminated from one side
light
light
light
Experiment 3:
light
tip replaced on one side of the remaining 
coleoptile that is then kept in the dark
coleoptile illuminated 
and the tip removed
PMT


--- Page Break ---

*P69506A01628*
16
	
 
 
	
	
Scientists concluded that these results suggest a plant growth substance is 
involved in regulating the phototropic response.
	
	
Discuss how the results of these experiments support the role of a plant growth 
substance in the phototropic response of plants.
	
	
Use the information for these experiments and your own knowledge to support 
your answer.
(6)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 5 = 10 marks)
PMT


--- Page Break ---

*P69506A01728*
Turn over     
17
	
 
 
6	 The nervous system is a complex collection of neurones and specialised cells that 
transmit impulses between different parts of the body.
	
(a)	 Which substance can transmit a nerve impulse from one neurone to the 
next one?
(1)
	
A	 acetylcholine
	
B	 ADP
	
C	 cholesterol
	
D	 NADP
	
(b)	 The diagram shows the change in membrane potential as an action potential is 
transmitted in a motor neurone.
time
membrane 
potential 
/ mV
1
2
3
30
0
–55
–70
	
	
Explain why the membrane potential changes between 1 and 2.
(2)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P69506A01828*
18
	
 
 
	
(c)	 Myelinated neurones are surrounded by a fatty sheath.
	
	
The graph shows the speed of conduction in myelinated neurones and 
non‑myelinated neurones.
myelinated neurones
non‑myelinated neurones
neurone diameter / μm
speed of 
conduction 
/ m s–1
0
5
10
15
20
25
30
140
120
100
80
60
40
20
0
	
	
(i)	 Calculate the percentage difference in the gradient of the myelinated and 
non‑myelinated neurones.
	
	
	
The gradient for non‑myelinated neurones is 0.5.
	
	
	
The equation for a straight line is  y = mx + c .
(3)
Answer ..............................................................%
PMT


--- Page Break ---

*P69506A01928*
Turn over     
19
	
 
 
	
	
(ii)	 Explain why the speed of conduction differs in myelinated and 
non‑myelinated neurones.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P69506A02028*
20
	
 
 
	
(d)	 The positron emission tomography (PET) images show the brain of an individual 
before (control) and after taking the drug cocaine.
(Source: © BROOKHAVEN NATIONAL LABORATORY / SCIENCE PHOTO LIBRARY)
	
	
Explain how positron emission tomography (PET) can be used to identify the 
change in activity in the brain after taking this drug.
(4)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 6 = 13 marks)
PMT


--- Page Break ---

*P69506A02128*
Turn over     
21
	
 
 
7	 Alpha‑1 antitrypsin (AAT) deficiency is an inherited disease that can affect different 
organ systems.
	
Alpha‑1 antitrypsin (AAT) is a protein produced in the liver.
	
(a)	 Investigation of the breathing of a patient with AAT deficiency found that the:
•	
resting tidal volume (VT) was 500 cm3
•	
dead space (DS) was 150 cm3
•	
resting respiratory rate (RR) was 12 breaths per minute.
	
	
Calculate the volume of air that enters the alveoli (AV) each hour.
AV = (VT – DS) × RR
	
	
Give your answer to 2 significant figures with appropriate units.
(3)
Answer ..............................................................
	
(b)	 Activity of the heart was investigated in the same patient.
	
	
The trace shows a normal electrocardiogram (ECG).
R
1.0 s
1 mV
S
Q
P
T
	
	
(i)	 Name the stage of the cardiac cycle at T on this ECG.
(1)
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P69506A02228*
22
	
 
 
	
	
(ii)	 The ECG of the patient with AAT is shown in the trace.
1.0 s
1 mV
	
	
	
Calculate the mean heart rate shown in this ECG trace.
(1)
Answer ..............................................................
	
	
(iii)	Compare and contrast the ECG trace of this patient with the normal ECG trace.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P69506A02328*
Turn over     
23
	
 
 
	
(c)	 One potential treatment for AAT deficiency uses adenoviruses to genetically 
modify cells in an affected person.
	
	
Adenoviruses contain double‑stranded DNA.
	
	
Explain how adenoviruses can be used to treat AAT deficiency in a person.
(4)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 7 = 12 marks)
PMT


--- Page Break ---

*P69506A02428*
24
	
 
 
8	 The scientific document you have studied is adapted from an article in Science Direct: 
Assessment of food toxicology by Alexander Gosslau.
	
Use the information from the scientific article and your own knowledge to answer the 
following questions.
	
(a)	 Explain how toxicants in food could cause Parkinson’s disease (paragraph 3).
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
	
(b)	 Suggest how the genes affected by toxicants can be identified (paragraph 4).
(2)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P69506A02528*
Turn over     
25
	
 
 
	
(c)	 Explain how scientists could determine the high degree of homology of genes 
between humans and zebrafish (paragraph 5).
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
	
(d)	 Suggest how electrophilic species (ES) of free radicals could be “involved in the 
modulation of gene expression” (paragraph 6).
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P69506A02628*
26
	
 
 
	
(e)	 Suggest how ES can damage mtDNA (paragraph 7).
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
	
(f)	 In the MTT assay, reduced NAD converts an MTT solution from yellow to purple.
	
	
Describe how the MTT assay could be used to show which of two drugs is more 
toxic to cells (paragraph 10).
(4)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P69506A02728*
27
	
 
 
	
(g)	 Explain the advantages of reprogramming ordinary somatic cells to behave like 
embryonic stem cells for use in stem cell‑based assays of toxicants (paragraph 11).
(2)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 8 = 20 marks)
TOTAL FOR PAPER = 90 MARKS
PMT


--- Page Break ---

*P69506A02828*
28
	
 
 
BLANK PAGE
PMT


--- Page Break ---

Turn over    
Paper
reference


*P69506A*
Pearson Edexcel International Advanced Level
Scientific article for use with Question 8
Do not return this Insert with the question paper.
Biology
International Advanced Level
UNIT 5: Respiration, Internal Environment, 
Coordination and Gene Technology
WBI15/01
Time 1 hour 45 minutes
P69506A
©2022 Pearson Education Ltd.
L:1/1/1/1/1/
PMT


--- Page Break ---

 
 
2
P69506A
Scientific article for use with Question 8
Assessment of food toxicology by Alexander Gosslau
1.	 The history of food toxicity might have started as early as Hippocrates made the statement 
“Let food be thy medicine and medicine thy food” which presaged the modern science by over 
two millennia ago. With the development of modern biochemistry, molecular biology, cell 
culture techniques, computer science and bioinformatics, it has been possible to identify and 
characterize potential toxicants in food.
2.	 There are two different related areas in the measurement of toxicants and toxicity in food: 
(1) actual measurements of the effects of toxicants in different models ranging from in vitro 
biochemical systems, cell‑based in vitro systems, animal in vivo models to clinical settings 
analyzing systemic or organ‑specific toxicity and (2) assessment and/or predictions of potential 
toxicants in food.
3.	 The mechanisms of toxicant effects are multifactorial interacting intrinsically and extrinsically 
with key molecules which play major roles in cell integrity, metabolism, signaling pathways, 
gene expression and translation. For a variety of toxicants their effects appear to converge on 
the generation of electrophilic species (ES) leading to oxidative stress and chronic inflammation. 
Oxidative reactions induced by toxicants lead to an accumulation of damaged macromolecules 
thus harming cells, tissues and organs. Therefore, toxicants may play central roles in cell death, 
chronic inflammation, aging and degenerative diseases such as Alzheimer’s, Parkinson’s and 
Huntington’s diseases, as well as multiple sclerosis, myocardial infarction, arteriosclerosis, 
diabetes, rheumatoid arthritis, sterility, cataracts and many others.
4.	 For in vitro assessment a variety of biochemical systems have been developed to analyze 
damaging effects on integrity or activity of key biomolecules. Such molecules are important in 
cell integrity, metabolism, signaling pathways, as well as gene expression and translation. The 
list of affected molecules is extensive and includes enzymes, receptors, membrane lipids, nucleic 
acids and/or factors involved in gene expression. On a cellular level, a variety of viability assays 
are routinely used to quantify effects of potential food toxicants for extrapolation of a range of 
dosages used for maximal tolerated concentrations for in vivo animal models and also clinical 
settings. In vivo rodent models still appear to be the gold standard for toxicity assessment but 
there are limitations of such traditional testing such as high costs, low throughput readouts, 
inconsistent responses, ethical issues and concerns of extrapolability to humans.
5.	 Another refinement in toxicity assessment is the installation of alternative lower hierarchy 
surrogate animal models such as zebrafish (Danio rerio), fruit flies (Drosophila melanogaster) 
or nematodes (Caenorhabditis elegans). These models offer an advantage in terms of ethical 
concerns, high throughput and genetic manipulation over traditional rodent models. The value 
of using alternative sub‑mammalian vertebrate and invertebrate models became evident by the 
surprising discovery of the high degree of homology of genes between humans and zebrafish, 
fruit flies or nematodes.
PMT


--- Page Break ---

 
 
3
Turn over    
P69506A
6.	 Although the mechanisms leading to toxic effects in humans are multifactorial, the majority of 
toxic effects appear to converge on the generation of free radicals. Different electrophilic species 
(ES) such as reactive oxygen species (ROS) or reactive nitrogen species (RNS) are capable of 
oxidizing virtually all biomolecules. Whereas a variety of toxicants generate ES directly, others 
induce a secondary response leading indirectly to generation of ES by immunocompetent 
leukocytes which play a key role in the inflammatory cascade. ES are also involved in the 
modulation of gene expression by interfering with transcription factors and/or DNA which can 
lead to mutations and carcinogenesis. The accumulation of damage to membrane lipids, cellular 
proteins, carbohydrates as well as nucleic acids harm the functioning of cells, tissues and organs. 
These and other observations strengthen the hypothesis that toxicants leading to oxidative stress 
and chronic inflammation play central roles in cell death, aging and degenerative diseases.
7.	 The oxidation of lipids, proteins, nucleic acids and carbohydrates generate a variety of damaging 
breakdown products which thus can lead to the onset of many degenerative diseases. 
Lipid peroxidation of cell structures containing lipids can lead to the generation of different 
toxic products including alcohols, ketones, alkanes, aldehydes and ethers which have the 
potential to contribute to cell damage, necrosis or apoptosis. Nucleic acids are delicate targets 
of ES leading to mutations. Damage of nucleic acids by ES may result in single and double 
strand breaks, DNA–DNA, DNA–protein, DNA–lipid adducts or numerous base modifications. 
Mitochondrial DNA (mtDNA) is particularly susceptible to oxidative damage because of the 
absence of associated histones, an incomplete mitochondrial DNA repair system and the 
generation of free radicals through electron leakage from the respiratory chain.
8.	 Testing whether a chemical can modulate the activity of particular enzyme or binding affinities 
to a particular receptor or other biomolecule is the most direct way to gain mechanistic insights 
into action at the molecular level. There are different biochemical in vitro assays which analyze 
the integrity or mutation of DNA and RNA, membrane lipids, as well as the binding and activity 
of various receptors, enzymes involved in signaling transduction, drug or neurotransmitter 
metabolism and many others.
9.	 The use of cellular models provides a much higher level of complexity than simple biochemical 
assays. A huge number of human cell lines are available and a variety of different cell‑based 
in vitro assays have been developed for screening of food toxicants.
10.	For general assessment of cytotoxicity an indirect measure of cell viability is usually performed 
and several cellular bioassays are routinely used integrating different cytotoxicity endpoints such 
as membrane leakage or cellular activity. Whereas the trypan blue, propidium iodide, crystal 
violet or lactate dehydrogenase assays are analyzing membrane integrity based on exclusion, 
other viability assays such as the neutral red, alamar blue or MTT assay are metabolic measures of 
cellular activity. Inhibitory concentrations (IC values) obtained by viability assays are then used for 
initial dose selection in testing on animals and humans.
	
In addition to the measurement of dyes, activity analysis of enzymes is also an established 
technique used to determine membrane integrity. Leakage of intracellular enzymes such as 
lactate dehydrogenase (LDH) or others into the extracellular medium is thus employed as 
indicator of cell membrane damage.
	
Damage of mitochondria is a major contributor to organ toxicity, such as of the liver, kidney, 
heart, muscle and the central nervous system, and mitochondrial dysfunction is increasingly 
implicated in a growing list of degenerative diseases.
PMT


--- Page Break ---

 
 
4
P69506A
11.	Recently, stem cell‑based assays are being discussed as source for various toxicological 
applications thanks to the Nobel Prize‑winning discovery of how to reprogram ordinary somatic 
cells to behave like embryonic stem cells. Human‑induced pluripotent stem cells (iPSCs) allow 
assays to consider an individual’s genetic background and potential epigenetic influences that 
affect the variability of the toxicity response. Stem cell‑based models are also of particular 
interest for toxicity measurements which either lack extrapolability in rodent models such as for 
genotoxicity, cardiotoxicity, respiratory toxicity or for different stages of disorders which largely 
remain unknown such as neurological disorders (depression, anxiety, Alzheimer’s and Parkinson’s 
disease), autoimmune diseases (multiple sclerosis, type I diabetes, asthma), systemic infection, 
cancer and others.
12.	While complex cell culture systems can provide unique insights into in vivo toxicology, they will 
never completely model the higher level interactions present in an intact organism. Therefore, 
the gold standard for toxicity assessment has been in vivo toxicology, where a particular molecule 
or complex food ingredients are given to animals to evaluate acute, subacute and chronic effects.
13.	The majority of animals used are rodents and to derive statistically significant results the numbers 
of animals needed for testing are enormous with an estimation of 7000 animals and tens of 
millions of dollars for each test compound in the pharmaceutical industry. Although the numbers 
of animals involved in food toxicity screening are decreasing, the numbers of compounds or 
food ingredients to be tested as well as the costs of the current in vivo assessment systems 
are exploding.
14.	More recently, the zebrafish D. rerio has been used as a vertebrate model organism for a wide 
variety of research including drug discovery and toxicology. The increased usage of zebrafish as 
in vivo model system reflects the striking similiar toxicity profile between humans and zebrafish 
due to substantial physiological, anatomic and genetic homology. The zebrafish model is also 
amenable to gene manipulation, is low in cost, has a short generation time and is particularly 
well suited for high‑throughput screening as well as microarray and proteomic studies. Since 
zebrafish larvae are transparent they are ideal for studies on organ morphology by in vivo 
imaging techniques in addition to more detailed studies by immunohistochemistry or in situ 
hybridization.
15.	Toxicity assessment in humans involves different fields such as clinical, forensic, environmental 
and regulatory toxicology. A systemic determination of toxicants in body tissues is usually 
obtained by biopsy or by analyzing body fluids such as blood and urine.
16.	A great deal of knowledge on toxicity in humans has been obtained by post mortem molecular 
and anatomic analysis of cells, tissues and organs. Forensic toxicology is very related to 
toxicologic pathology but focusing more on the application to the purposes of the law. By virtue 
of advances in nanotechnology and its application in food industry, the newly created discipline 
of nanotoxicology investigates safety or potential hazards of nanoparticles. Another dimension 
refers to genetically modified organisms (GMO) or genetically modified food (GMF) as potential 
sources of toxicity. All the different disciplines of toxicity assessment in humans are not mutually 
exclusive but rather highly interconnected. The goal is to identify and understand the molecular 
mechanisms of toxicants causing adverse effects in order to ultimately prevent their intake thus 
increasing food safety.
PMT
